Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) and Galena Biopharma (NASDAQ:GALE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitabiliy, dividends, institutional ownership, risk and earnings.

Earnings & Valuation

This table compares Adamis Pharmaceuticals Corporation and Galena Biopharma’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Adamis Pharmaceuticals Corporation $9.51 million 15.07 -$21.54 million N/A N/A
Galena Biopharma N/A N/A -$27.83 million ($0.94) -0.59

Adamis Pharmaceuticals Corporation has higher revenue and earnings than Galena Biopharma.

Risk & Volatility

Adamis Pharmaceuticals Corporation has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Comparatively, Galena Biopharma has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500.

Institutional & Insider Ownership

11.3% of Adamis Pharmaceuticals Corporation shares are owned by institutional investors. Comparatively, 22.2% of Galena Biopharma shares are owned by institutional investors. 9.6% of Adamis Pharmaceuticals Corporation shares are owned by insiders. Comparatively, 0.8% of Galena Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Adamis Pharmaceuticals Corporation and Galena Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adamis Pharmaceuticals Corporation -197.55% -87.56% -54.69%
Galena Biopharma N/A -14.89% -5.27%

Analyst Ratings

This is a summary of current ratings and recommmendations for Adamis Pharmaceuticals Corporation and Galena Biopharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adamis Pharmaceuticals Corporation 0 0 2 0 3.00
Galena Biopharma 0 4 0 0 2.00

Adamis Pharmaceuticals Corporation presently has a consensus target price of $7.50, suggesting a potential upside of 44.23%. Galena Biopharma has a consensus target price of $2.78, suggesting a potential upside of 403.81%. Given Galena Biopharma’s higher probable upside, analysts plainly believe Galena Biopharma is more favorable than Adamis Pharmaceuticals Corporation.

Summary

Galena Biopharma beats Adamis Pharmaceuticals Corporation on 6 of the 11 factors compared between the two stocks.

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

About Galena Biopharma

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.

Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.